Antibody persistence after primary and booster doses of a pentavalent vaccine against diphtheria, tetanus, acellular pertussis, inactivated poliovirus, haemophilus influenzae type b vaccine among thai children at 18-19 months of age

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 43, Issue 2, 2012, Pages 442-454

  Chotpitayasunondh, Tawee ^a   Thisyakorn, Usa ^b   Pancharoen, Chitsanu ^b   Chuenkitmongkol, Sunate ^c   Ortiz, Esteban ^d  

^a QUEEN SIRIKIT NATIONAL INSTITUTE OF CHILD HEALTH   (Thailand)

^b KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^c Sanofi Pasteur   (Thailand)

^d SANOFI PASTEUR   (France)

Author keywords

Acellular pertussis; Booster vaccination; Hib conjugate vaccine; Immunogenicity; Inactivated polio vaccine; Pentavalent combined vaccine; Safety

Indexed keywords

EID: 84862536215     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Barret AS, Ryan A, Breslin A, Cullen L, et al. Pertussis outbreak in northwest Ireland, January - June 2010. Euro Surveill 2010; 15 (35).
2. Bonmarin I, Levy-Bruhl D, Baron S, et al. Pertussis surveillance in French hospitals: results from a 10 year period. Euro Surveill 2007; 20: 12 (1).
3. Cameron C, Pebody R. Introduction of pneumococcal conjugate vaccine to the UK childhood immunisation programme, and changes to the meningitis C and Hib schedules. Euro Surveill 2006; 11 (9).
4. Capeding RM, Cadorna-Carlos J, Book-Montellano M, Ortiz E. Immunogenicity and safety of a DTaP-IPV//PRP~T combination vaccine at 6, 10, 14 weeks of age (EPI schedule) and concomitant Hepatitis B vaccination at birth, 6, 14 or 6, 10, 14 weeks of age. Bull World Health Organ 2008; 86: 443-51.
5. Carlsson RM, Claesson BA, Selstam U, et al. Safety and immunogenicity of a combined diphtheria, tetanus, acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J 1998; 17: 1026-33.
6. Carlsson RM, Claesson BA, Fagerlund E, Knutsson N, Laudin C. Antibody persistence in five-year old children who received a pentavalent combination vaccine in infancy. Pediatr Infect Dis J 2002; 21: 1535-41.
7. Carlsson RM, Trollfors B. Control of pertussis- lessons learnt from a 10-year surveillance programme in Sweden. Vaccine 2009; 27: 5709-18.
8. Cruces RP, Donoso FA, Camacho AJ, Llorente HM. Invasive infections caused by Haemophilus influenzae type b after the institution of the conjugated vaccine on the expanded programme on immunization in Chile. Rev Chilena Infectol 2006; 23: 50-4.
9. Dutta AK, Verghese VP, Pemde HK, Mathew LG, Ortiz E. Immunogenicity and safety of a pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type B conjugate combination vaccine (Pentaxim) with hepatitis B vaccine. Indian Pediatr 2009; 46: 975-82.
10. th Asian Pacific Congress of Pediatrics, October 2009.
11. Edwards KM, Decker M. Pertussis vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccines. 5th ed. Philadelphia: Saunders, 2008; 21: 467-517.
12. Eglund JA, Decker MD, Edwards KM, Pichichero ME, Steinhoff MC, Anderson EL. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study. Pediatrics 1994; 93: 37-43.
13. Fitzgerald M, Canny M, O'Flanagan D. Vaccination catch-up campaign in response to recent increase in Hib infection in Ereland. Euro Surveill 2005; 10: E050929.2.
14. Grimprel E, Bégué P, Anjak I, Njamkepo E, François P, Guiso N. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. Clin Diagn Lab Immunol 1996; 3: 93-7.
15. Guiso N, Njamkepo E, Viéle Sage, et al. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine 2007; 25: 1390-7.
16. Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 2006; 118: 978-84.
17. nd ed. New York, NY: Marcel Dekker, 1997: 387-416.
18. Johnson NG, Ruggeberg JU, Balfour GF, et al. Haemophilus influenzae type b reemergence after combination immunization. Emerg Infect Dis 2006; 12: 937-41.
19. Kanra G, Selier T, Yurdakök K, et al. Immunogencity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTacP-IPV//PRP-T) administered simultaneously with a hepatitis B vaccine at two, three and four months of life. Vaccine 2000; 18: 947-54.
20. Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology 2004; 113: 163-74.
21. Ladhani S, Heath PT, Slack MP, et al. Haemophilus influenzae serotype b conjugate vaccine failure in twelve countries with established national childhood immunization programmes. Clin Microbiol Infect 2010; 16: 948-54.
22. Lagos R, Kotloff, KL Hoffenbach A, et al. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six month-old Chilean infants. Pediatr Infect Dis J 1998; 17: 294-304.
23. Langue J, Matisse N, Pacoret P, Undreiner F, Boisnard F, Soubeyrand B. Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age. Vaccine 2004; 22: 1406-14.
24. Li RC, Li XF, Li YP, et al. Antibody persistence at 18-20 months of age and immunogenicity and safety of a combined DTaP-IPV// PRP~T vaccine compared to separate vaccines (DTaP, PRP~T and IPV) following primary vaccination of healthy infants in the Peoples' Republic of China. Vaccine 2011; 29: 9337-44.
25. Madhi SA, Cutland C, Jones S, et al. Immunogenicity and safety of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim™) and monovalent hepatitis B vaccine at 6, 10 and 14 months of age in infants in South Africa. S Afr Med J 2011a; 101: 126-31.
26. Madhi SA, Cutland C, Jones S, et al. One-year post-primary antibody persistence and booster immune response to a DTaP-IPV// PRP-T Vaccine (Pentaxim) given at 18-19 months of age in South African children primed at 6, 10 and 14 weeks of age with the same vaccine. S Afr Med J 2011b; 101: 876-83.
27. Mallet E, Fabre P, Pines E, et al. Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants. Pediatr Infect Dis J 2000; 19: 1119-27.
28. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998a; 17: 873-90.
29. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998b; 17: 857-72.
30. Pichichero ME, Deloria MA, Rennels MB, et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics 1997; 100: 772-88.
31. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17: 1055-65.
32. Plotkin SA, Liese J, Madhi SA, Ortiz E. A DTaP-IPV//PRP-T vaccine (Pentaxim): a review of 16 years' clinical experience. Expert Rev Vaccines 2011; 10: 981-1005.
33. Rennels MB. Need for polio boosters after age two years. Vaccine 2009; 27: 179-8.
34. Rendi-Wagner P, Paulke-Korinek M, Stanek G, et al. Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria. Pediatr Infect Dis J 2007; 26: 806-10.
35. Ryan EJ, Nilsson L, Kjellman N, et al. Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens. Clin Exp Immunol 2000; 12: 193-200.
36. Swedish Institute for Infectious Disease Control. Eleven year report - Pertussis surveillance in Sweden (6:2009). Progress Report October 1, 1997 - December 31, 2008, with an executive summary. Stockholm: Swedish Institute for Infectious Disease Control, 2009. [Cited 2011 Jan 04]. Available from: URL: http://www.smittskyddsinstitutet.se/ upload/Publikationer/smirapport-06-2009.pdf
37. Thisyakorn U, Pancharoen C, Chuenkitmongkol S, et al. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (PentaximTM) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine. Southeast Asian J Trop Med Public Health 2009; 40: 282-94.
38. Thisyakorn U, Chotpitayasunondh T, Pancharoen C, et al. Evaluation of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, HIB conjugate combined vaccine (PentaximTM) at 2, 4, ad 6 months of age plus hepatitis B vaccine at birth, 2, and 6 months of age in infants in Thailand. Southeast Asian J Trop Med Public Health 2010; 41: 450-62.
39. Tichmann I, Grunert D, Habash S, et al. Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type B vaccines and evaluation of booster vaccination. Hum Vaccines 2006; 2: 249-54.
40. Tiru M, Hallander HO, Gustafsson L, et al. Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine 2000;18: 2295-306.
41. Vidor E, Plotkin SA. Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations. Hum Vaccines 2008; 4: 328-40.
42. World Health Organization (WHO). Expanded programme on immunization. Global advisory group-part 1. Wkly Epidemiol Rec 1992; 67: 11-15.
43. World Health Organization (WHO). The Children's Vaccine Initiative and the Global Programme for Vaccines and Immunization. Recommendations from the Special Advisory Group of Experts. Part 1. Wkly Epidemiol Rec 1997; 72: 237-43.
44. World Health Organization (WHO). Global Programme for Vaccines and Immunization (GPV): The WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 1998; 73: 64-8.
45. World Health Organization (WHO). Pertussis vaccines. WHO position paper. Wkly Epidemiol Rec 2005; 80: 31-9.
46. World Health Organization (WHO). Thailand 2007 EPI Fact Sheet. [Cited 2011 Dec 6]. Available from: URL: http://www.searo.who.int/vaccine/LinkFiles/EPI2007/Thailand07.pdf
47. World Health Organization (WHO). Pertussis vaccines WHO position paper. Weekly Epidemiol Rec 2010a; 85: 385-400.
48. World Health Organization (WHO). Vaccine preventable diseases monitoring system 2010 Global summary: Country profile selection center. Geneva: WHO, 2010b. Available from: URL: http://apps.who.int/immunization_monitoring/en/globalsummary/countryprofileselect.cfm
49. World Health Organization (WHO). United Nations prequalified vaccines 2010 (WHO list of vaccines for purchase by UN agencies as of May 2010). Geneva: WHO, 2010c. [Cited 2011 Dec 6]. Available from: URL: http://www.who.int/immunization_standards/vaccine_quality/PQ_vaccine_list_en/en/index.html
50. World Health Organization (WHO). Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Weekly Epidemiol Rec 2010d; 85: 213-28.